The Milwaukee-based biopharmaceutical company, founded in 2006, is focused on discovering and marketing first-in-class therapies to treat central nervous system disorders. Their drug development program targets a unique pathway to restore glutamatergic neurotransmission and imbalances in oxidative stress, which are key contributors to impaired cortical function linked to multiple CNS disorders. Their lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that currently has no FDA-approved treatment and a high level of patient need. The company's mission is to redefine what is possible in the treatment of CNS disorders.